Meeting
2023 ASCO Annual Meeting
Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.
Authors
Joaquin Martinez-Lopez
Departamento de Hematología, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain
Joaquin Martinez-Lopez , Sandy Wai Kuan Wong , Nieves Lopez-Muñoz , Natasha Bahri , Shagun Arora , Mikaela Kuan , Sara Dorado , Santiago Barrio , Alfred Chung , Thomas G. Martin , Jeffrey Lee Wolf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8028)
DOI
10.1200/JCO.2023.41.16_suppl.8028
Abstract #
8028
Poster Bd #
20
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Minimal residual disease clinical monitoring and depth of response in multiple myeloma.
First Author: Joaquin Martinez-Lopez
Poster
2023 ASCO Annual Meeting
Comparison of next-generation sequencing and flow cytometry in detecting minimal residual disease in adult acute lymphoid leukemia: Evaluating clinical outcomes in a single-center study.
First Author: Vinay Nittur
Poster
2023 ASCO Annual Meeting
Dynamic ctDNA to inform the precise management of resected NSCLC: LUNGCA-2 study.
First Author: Liang Xia
Poster
2021 ASCO Annual Meeting
Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma.
First Author: Binod Dhakal